Dilated Cardiomyopathy (DCM) Market View 2025: Marketed Drugs, Pricing and Reimbursement, Pipeline, Clinical Trials, Epidemiology, Commercial and Deals Landscape

Discover the evolving landscape of Dilated Cardiomyopathy Therapeutics. In 2024, anticipate over 3 million DCM cases in 16 countries. Key treatments include beta-blockers and ACE inhibitors, while 34 molecules progress in the pipeline. Explore market insights, competitive analyses, and future industry catalysts.


Dublin, June 18, 2025 (GLOBE NEWSWIRE) -- The "Dilated Cardiomyopathy (DCM): Market View" report has been added to ResearchAndMarkets.com's offering.

This report presents a data-driven overview of the current and future competitive landscape in Dilated Cardiomyopathy (DCM) Therapeutics. In 2024, there are expected to be over three million diagnosed prevalent cases of DCM across 16 countries included in the forecast.

Treatment is primarily focused on symptom management, using beta-blockers, ACE inhibitors, ARBs, MRAs, and SGLT2 inhibitors. Currently, 34 molecules are in development for DCM across various pipeline stages.

Over the past decade, the U.S. led in clinical trial activity with nearly 110 trial sites. In terms of deal activity, acquisitions were most common in North America, while licensing agreements dominated in South and Central America, Africa, and the Asia-Pacific regions.

Reasons to Buy

  • Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
  • Develop business strategies by understanding the trends shaping and driving the Dilated Cardiomyopathy Therapeutics market.
  • Drive revenues by understanding the key trends, innovative products and technologies, and companies likely to impact the global Dilated Cardiomyopathy Therapeutics market in the future.
  • Formulate effective sales and marketing strategies by understanding the competitive landscape and analyzing the performance of various competitors.
  • Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
  • Organize your sales and marketing efforts by identifying the market categories that present the maximum opportunities for consolidations, investments, and strategic partnerships.

Components of the report include:

  • Disease Landscape
  • Disease Overview
  • Epidemiology Overview
  • Treatment Overview
  • Marketed Products Assessment
  • Breakdown by Mechanism of Action, Route of Administration
  • Product Profiles with Sales Forecast
  • Pricing and Reimbursement Assessment
  • Annual Therapy Cost
  • Time to Pricing and Time to Reimbursement
  • Pipeline Assessment
  • Breakdown by Development Stage, Mechanism of Action, Molecule Type, Route of Administration
  • Product Profiles with Sales Forecast
  • Late-to-mid-stage Pipeline Drugs
  • Phase Transition Success Rate and Likelihood of Approval
  • Clinical Trials Assessment
  • Breakdown of Trials by Phase, Status, Virtual Components, Sponsors, Geography, and Endpoint Status
  • Enrolment Analytics, Site Analytics, Feasibility Analysis
  • Deals Landscape
  • Mergers, Acquisitions, and Strategic Alliances by Region
  • Overview of Recent Deals
  • Commercial Assessment
  • Key Market Players
  • Future Market Catalysts

Key Topics Covered:

1 Preface
1.1 Contents
1.2 Report Scope
1.3 List of Tables and Figures
1.4 Abbreviations

2 Key Findings

3 Disease Landscape
3.1 Disease Overview
3.2 Epidemiology Overview
3.3 Treatment Overview

4 Marketed Drugs Assessment
4.1 Leading Marketed Drugs
4.2 Overview by Mechanism of Action
4.3 Overview by Molecule Type
4.4 Product Profiles and Sales Forecast

5 Pricing and Reimbursement Assessment
5.1 Annual Cost of Therapy
5.2 Time to Pricing and Reimbursement

6 Pipeline Drugs Assessment
6.1 Mid-to-late-stage Pipeline Drugs
6.2 Overview by Development Stage
6.3 Overview by Mechanism of Action
6.4 Overview by Molecule Type
6.5 Drug Specific Phase Transition Success Rate (PTSR) and Likelihood of Approval (LoA)
6.6 Therapy Area and Indication-specific PTSR and LoA

7 Clinical Trials Assessment
7.1 Historical Overview
7.2 Overview by Phase
7.3 Overview by Status
7.4 Overview by Phase for Ongoing and Planned Trials
7.5 Trials with Virtual Components
7.6 Overview of Trials by Geography
7.7 Single-Country and Multinational Trials by Region
7.8 Top 20 Sponsors with Breakdown by Phase
7.9 Top 20 Sponsors with Breakdown by Status
7.10 Overview by Endpoint Status
7.11 Overview by Race and Ethnicity
7.12 Enrollment Data
7.13 Top 20 countries for Trial Sites
7.14 Top 20 Sites Globally
7.15 Feasibility Analysis - Geographic Overview
7.16 Feasibility Analysis - Benchmark Models

8 Deals Landscape
8.1 Mergers, Acquisitions, and Strategic Alliances by Region
8.2 Recent Mergers, Acquisitions, and Strategic Alliances

9 Commercial Assessment
9.1 Key Market Players

10 Future Market Catalysts

11 Appendix

For more information about this report visit https://www.researchandmarkets.com/r/w0z52z

About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

 

Kontaktdaten